Observational studyKidney & blood pressure research2026
Neutrophil Gelatinase-Associated Lipocalin for the Assessment of Persistent Renal Dysfunction after Acute Kidney Injury.
Observational study in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal injury is a significant complication in ST-segment elevation myocardial infarction (STEMI) and is associated with poor outcomes. The recently introduced term acute kidney disease (AKD) describes persistent renal dysfunction lasting 7-90 days post-acute kidney injury (AKI). Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker for tubular injury, has shown promise in predicting AKI. This study aimed to evaluate NGAL's diagnostic utility for predicting AKD in STEMI patients.
methodsThis prospective observational study included 312 patients admitted with STEMI. NGAL levels were measured within 2 h of admission. AKI and AKD were defined using KDIGO criteria, and patients with chronic inflammation or end-stage renal disease were excluded. Receiver operating characteristic (ROC) analysis was performed to evaluate NGAL's predictive value for AKD and its optimal value for prediction.
resultsOverall, 64 patients developed AKI (21%), with 30 (47%) progressing to AKD. Patients with AKD had higher admission NGAL levels (median 165 ng/mL) compared to those with resolved AKI (112 ng/mL) or no AKI (88 ng/mL, p < 0.001). NGAL had a good predictive ability for AKD (area under the ROC of 0.784), with a threshold of >150 ng/mL having 65% sensitivity and 77% specificity for correct prediction. Multivariate analysis confirmed NGAL >150 ng/mL as an independent predictor of AKD (HR 6.4, 95% CI 1.94-21.06, p < 0.001)).
conclusionElevated NGAL levels are independently associated with AKD development in STEMI patients. These findings suggest NGAL could be a valuable biomarker for early risk stratification, supporting timely interventions to mitigate persistent renal injury. Further research is warranted to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.